secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001140361-24-023815
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech appoints Stephan Toutain as COO; grants 200,000-share option
------------------------------------------------------------------------

- Stephan Toutain named COO effective May 1, 2024; brings 30+ years pharma experience including oncology and orphan drugs.
- Annual salary $450,000; eligible for annual performance bonus of 40% of base salary.
- Received inducement stock option for 200,000 shares at $3.61 per share, vesting over four years under Nasdaq Listing Rule 5635(c)(4).
- Prior roles include COO at Anavex Life Sciences (2018-2024) and leadership at Alnylam, Sarepta, Alexion, Celgene, and Johnson & Johnson.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124023815/0001140361-24-023815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124023815/ef20028223_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-023815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer